E-Home Household Service Holdings Ltd. — Form 20-F Summary
Period clarification: The supplied filing is the annual report for the fiscal year ended June 30, 2022, with comparisons to fiscal 2021 and 2020. It is not a 2021 Q4 report; quarterly results are not presented here. Figures are in U.S. dollars unless noted.
Business context
E-Home is a Cayman Islands holding company whose operations and revenue are generated primarily by subsidiaries in China. It provides home appliance installation and maintenance, housekeeping, and senior care services through an online platform and third-party service providers. In October 2021, it dissolved its former VIE structure after acquiring the operating entities directly.
Financial performance
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $63.75 million | $74.53 million |
| Gross profit / gross margin | $19.36 million / 30.4% | $26.21 million / 35.2% |
| Operating income (loss) / margin | ($0.85 million) / (1.3%) | $9.07 million / 12.2% |
| Net income (loss) | ($5.43 million) | $6.40 million |
| Operating cash flow | $4.37 million | $8.67 million |
| Cash and cash equivalents at year-end | $54.84 million | $52.41 million |
- Installation and maintenance revenue fell 22.4% to $40.02 million; housekeeping revenue declined 2.7% to $16.34 million. Senior care revenue rose 22.4% to $7.39 million. The company attributed the declines mainly to COVID-related restrictions and lockdowns in China.
- Operating costs and expenses pressured profitability: cost of revenue was $44.39 million, while sales and marketing expense rose 16.6% to $11.99 million and general and administrative expense rose 19.7% to $8.22 million. Gross margin declined about 4.8 percentage points.
- Other expenses totaled $2.48 million, including a $2.00 million fair-value loss tied to the proposed Lianbao acquisition, $0.40 million in convertible-note financing-cost accretion, and $0.26 million in interest expense.
- Investing cash outflow was $7.40 million, principally for property and equipment, right-of-use assets, and investments. Financing provided $7.35 million net, including $8.445 million of convertible-note proceeds less issuance costs.
- At June 30, 2022, current assets were $67.00 million and current liabilities $8.19 million, implying working capital of approximately $58.80 million. Total liabilities were $15.96 million, including $5.93 million net carrying value of convertible notes, $2.25 million of operating lease liabilities, and $0.43 million of finance lease liabilities. Cash exceeded the reported note and lease liabilities, but much of the cash was held in China and subject to transfer and currency-control restrictions.
Material changes, outlook, and risks
- Revenue declined 14.5%, and the company swung from a $6.40 million net profit to a $5.43 million net loss. Management said results for FY2023 and beyond remained uncertain, with further COVID outbreaks or restrictions potentially affecting operations. No numerical guidance was provided.
- The company reported $3.6 million of FY2022 marketing and administrative share-based compensation combined, including shares issued to directors and consultants; reported share counts and per-share amounts were subsequently adjusted for a 1-for-20 reverse split effective October 4, 2022.
- Convertible notes issued in December 2021 and May 2022 have two-year maturities and 8% stated interest. Conversion is generally at 85% of the lowest daily VWAP over the preceding ten trading days, subject to contractual and Nasdaq limits. The notes also include default-trigger provisions and placement-agent warrants, creating potential dilution and financing risk.
- After year-end, the company agreed to acquire 55% of Zhongrun (Fujian) Pharmaceutical for RMB3 million plus 28,041,992 ordinary shares, issued July 8, 2022 at a stated fair value of $8.50 million. Purchase-price allocation was still being evaluated. The filing also describes other proposed or uncompleted acquisitions and potential equity financings.
- Management reported material weaknesses in internal control over financial reporting, citing insufficient qualified U.S. GAAP/SEC reporting personnel and inadequate review resources. Disclosure controls were assessed as ineffective. Management planned to hire and train accounting staff; the auditor did not provide an internal-control effectiveness opinion.
- Key risks include PRC regulatory and legal uncertainty, restrictions on moving cash out of China, data/privacy compliance, currency movements, service-provider and customer-service dependence, competition, and potential U.S. trading restrictions if PCAOB audit access changes. The company said its auditor was then subject to PCAOB inspection and no PRC approval or inquiry regarding its listing had been received as of the report date.
- The company reported no material litigation known to management, no declared dividends, and no dividends expected in the foreseeable future. Its financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Reconcile the reported net loss and cash flow disclosures, including inconsistent narrative figures in the filing, against the audited statements and notes.
- Confirm the status, final consideration, share issuance effects, and accounting for the Zhongrun acquisition and other proposed acquisitions; review the impact of the reverse split on current share counts and convertible securities.
- Review the convertible-note conversion terms, floors and limits, outstanding principal, warrants, and potential dilution under current share prices.
- Assess whether the stated cash balance is accessible for offshore obligations, given PRC remittance rules, and confirm cash location and restrictions.
- Track remediation of internal-control weaknesses and monitor whether subsequent filings report effective controls or further accounting adjustments.